Pharmaceutical major Cipla Ltd on Tuesday reported a 30% year-on-year (YoY) rise in its consolidated net profit, which stood at Rs 1,222 crore for the fourth quarter ended March 31, 2025.The strong performance was driven by higher sales in key markets including India, the United States, and Africa.The Mumbai-based company had reported a net profit of Rs 939 crore in the corresponding quarter of the previous fiscal.Total revenue from operations rose to Rs 6,730 crore in the March quarter, up from Rs 6,163 crore a year earlier, according to the company’s regulatory filing, as reported by PTI.In the domestic market, revenue increased 8% to Rs 2,622 crore, compared to Rs 2,417 crore in Q4FY24. Revenue from North America rose 2% year-on-year to Rs 1,919 crore, up from Rs 1,875 crore, while revenue from Africa posted a robust 20% growth, reaching Rs 1,019 crore during the quarter.For the full fiscal year FY25, Cipla reported a consolidated net profit of Rs 5,272 crore, marking a 28% increase over Rs 4,122 crore in FY24. Revenue from operations also grew, reaching Rs 27,548 crore as against Rs 25,774 crore in the previous financial year.“Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front,” said Cipla Managing Director and Global CEO Umang Vohra.The company’s Board of Directors has approved a total dividend of Rs 16 per share for FY25. This includes a final dividend of Rs 13 per share and a special dividend of Rs 3 per share, the latter announced to mark Cipla’s 90th anniversary. The dividend is based on shares with a face value of Rs 2 each.Shares of Cipla ended Tuesday’s trading session 0.49% higher at Rs 1,519.45 apiece on the BSE.
